Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial
Standard
Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial. / Koehler, Friedrich; Koehler, Johanna; Bramlage, Peter; Vettorazzi, Eik; Wegscheider, Karl; Lezius, Susanne; Spethmann, Sebastian; Iakoubov, Roman; Vijayan, Anjaly; Winkler, Sebastian; Melzer, Christoph; Schütt, Katharina; Dessapt-Baradez, Cécile; Paar, W Dieter; Koehler, Kerstin; Müller-Wieland, Dirk.
in: CARDIOVASC DIABETOL, Jahrgang 23, Nr. 1, 12.06.2024, S. 198.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial
AU - Koehler, Friedrich
AU - Koehler, Johanna
AU - Bramlage, Peter
AU - Vettorazzi, Eik
AU - Wegscheider, Karl
AU - Lezius, Susanne
AU - Spethmann, Sebastian
AU - Iakoubov, Roman
AU - Vijayan, Anjaly
AU - Winkler, Sebastian
AU - Melzer, Christoph
AU - Schütt, Katharina
AU - Dessapt-Baradez, Cécile
AU - Paar, W Dieter
AU - Koehler, Kerstin
AU - Müller-Wieland, Dirk
N1 - © 2024. The Author(s).
PY - 2024/6/12
Y1 - 2024/6/12
N2 - BACKGROUND: The TIM-HF2 study demonstrated that remote patient management (RPM) in a well-defined heart failure (HF) population reduced the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death during 1-year follow-up (hazard ratio 0.80) and all-cause mortality alone (HR 0.70). Higher rates of hospital admissions and mortality have been reported in HF patients with diabetes compared with HF patients without diabetes. Therefore, in a post-hoc analysis of the TIM-HF2 study, we investigated the efficacy of RPM in HF patients with diabetes.METHODS: TIM-HF2 study was a randomized, controlled, unmasked (concealed randomization), multicentre trial, performed in Germany between August 2013 and May 2018. HF-Patients in NYHA class II/III who had a HF-related hospital admission within the previous 12 months, irrespective of left ventricular ejection fraction, and were randomized to usual care with or without added RPM and followed for 1 year. The primary endpoint was days lost due to unplanned cardiovascular hospitalization or due to death of any cause. This post-hoc analysis included 707 HF patients with diabetes.RESULTS: In HF patients with diabetes, RPM reduced the percentage of days lost due to cardiovascular hospitalization or death compared with usual care (HR 0.66, 95% CI 0.48-0.90), and the rate of all-cause mortality alone (HR 0.52, 95% CI 0.32-0.85). RPM was also associated with an improvement in quality of life (mean difference in change in global score of Minnesota Living with Heart Failure Questionnaire score (MLHFQ): - 3.4, 95% CI - 6.2 to - 0.6).CONCLUSION: These results support the use of RPM in HF patients with diabetes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01878630.
AB - BACKGROUND: The TIM-HF2 study demonstrated that remote patient management (RPM) in a well-defined heart failure (HF) population reduced the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death during 1-year follow-up (hazard ratio 0.80) and all-cause mortality alone (HR 0.70). Higher rates of hospital admissions and mortality have been reported in HF patients with diabetes compared with HF patients without diabetes. Therefore, in a post-hoc analysis of the TIM-HF2 study, we investigated the efficacy of RPM in HF patients with diabetes.METHODS: TIM-HF2 study was a randomized, controlled, unmasked (concealed randomization), multicentre trial, performed in Germany between August 2013 and May 2018. HF-Patients in NYHA class II/III who had a HF-related hospital admission within the previous 12 months, irrespective of left ventricular ejection fraction, and were randomized to usual care with or without added RPM and followed for 1 year. The primary endpoint was days lost due to unplanned cardiovascular hospitalization or due to death of any cause. This post-hoc analysis included 707 HF patients with diabetes.RESULTS: In HF patients with diabetes, RPM reduced the percentage of days lost due to cardiovascular hospitalization or death compared with usual care (HR 0.66, 95% CI 0.48-0.90), and the rate of all-cause mortality alone (HR 0.52, 95% CI 0.32-0.85). RPM was also associated with an improvement in quality of life (mean difference in change in global score of Minnesota Living with Heart Failure Questionnaire score (MLHFQ): - 3.4, 95% CI - 6.2 to - 0.6).CONCLUSION: These results support the use of RPM in HF patients with diabetes.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01878630.
KW - Humans
KW - Heart Failure/mortality
KW - Male
KW - Female
KW - Aged
KW - Middle Aged
KW - Time Factors
KW - Treatment Outcome
KW - Germany/epidemiology
KW - Telemedicine
KW - Diabetes Mellitus/mortality
KW - Risk Factors
KW - Hospitalization
KW - Cause of Death
KW - Aged, 80 and over
KW - Patient Admission
U2 - 10.1186/s12933-024-02285-0
DO - 10.1186/s12933-024-02285-0
M3 - SCORING: Journal article
C2 - 38867198
VL - 23
SP - 198
JO - CARDIOVASC DIABETOL
JF - CARDIOVASC DIABETOL
SN - 1475-2840
IS - 1
ER -
